龍津藥業(002750.SZ):注射用燈盞花素擬中選省際聯盟集中帶量採購
格隆匯12月22日丨龍津藥業(002750.SZ)公佈,公司近期參與了中成藥省際聯盟集採領導小組辦公室組織的中成藥省際聯盟集中帶量採購報價,根據中成藥省際聯盟集採領導小組辦公室於2021年12月21日發佈的《中成藥省際聯盟集中帶量採購擬中選結果公示》,公司產品注射用燈盞花素擬中選省際聯盟集中帶量採購。
藥品名稱:注射用燈盞花素;規格:10mg、25mg、50mg(以野黃芩苷計);
功能主治:活血化瘀,通絡止痛。用於中風及其後遺症、冠心病、心絞痛;
擬中選基準價格:75.31元/盒(10瓶/盒,以報價代表品25mg規格計,價格降幅為67%,其他規格按報價代表品的降幅等比下調價格)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.